Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy · 10.05.2024
DOI: 10.1128/aac.01570-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 10.05.2024. Verfasst von Christophe Le Terrier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Escherichia coli, Microbial Sensitivity Tests, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Fribourg.
Abstract (Originalsprache)
Xeruborbactam is a newly developed β-lactamase inhibitor designed for metallo-β-lactamases (MBLs). This study assessed the relative inhibitory properties of this novel inhibitor in comparison with another MBL inhibitor, namely taniborbactam (TAN), against a wide range of acquired MBL produced either in Escherichia coli or Pseudomonas aeruginosa . As observed with taniborbactam, the combination of xeruborbactam (XER) with β-lactams, namely, ceftazidime, cefepime and meropenem, led to significantly decreased MIC values for a wide range of B1-type MBL-producing E. coli , including most recombinant strains producing NDM, VIM, IMP, GIM-1, and DIM-1 enzymes. Noteworthily, while TAN-based combinations significantly reduced MIC values of β-lactams for MBL-producing P. aeruginosa recombinant strains, those with XER were much less effective. We showed that this latter feature was related to the MexAB-OprM efflux pump significantly impacting MIC values when testing XER-based combinations in P. aeruginosa . The relative inhibitory concentrations (IC 50 values) were similar for XER and TAN against NDM and VIM enzymes. Noteworthily, XER was effective against NDM-9, NDM-30, VIM-83, and most of IMP enzymes, although those latter enzymes were considered resistant to TAN. However, no significant inhibition was observed with XER against IMP-10, SPM-1, and SIM-1 as well as the representative subclass B2 and B3 enzymes, PFM-1 and AIM-1. The determination of the constant inhibition ( K i ) of XER revealed a much higher value against IMP-10 than against NDM-1, VIM-2, and IMP-1. Hence, IMP-10 that differs from IMP-1 by a single amino-acid substitution (Val67Phe) can, therefore, be considered resistant to XER.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
- Infectious Disease Department, University hospital of Toulouse, Toulouse, France.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland.
ORCID-Profile: Christophe Le Terrier, Jacqueline Findlay, Patrice Nordmann, Laurent Poirel
Förderung
- University of Fribourg
Zitieren
APA
Le Terrier, C., Freire, S., Viguier, C., Findlay, J., Nordmann, P., & Poirel, L. (2024). Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01570-23
Vancouver
Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01570-23
BibTeX
@article{LeTerrier2024,
author = {Le Terrier, Christophe and Freire, Samanta and Viguier, Clément and Findlay, Jacqueline and Nordmann, Patrice and Poirel, Laurent},
title = {Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01570-23}
}
EUVIMED